-
EP4337257
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4337257
| EP4337257 - ANTIBODY COMPOSITION [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 16.02.2024 Database last updated on 22.08.2024 | |
| Former | The international publication has been made Status updated on 29.11.2022 | ||
| Former | unknown Status updated on 01.07.2022 | Most recent event Tooltip | 19.07.2024 | Change: Validation states | published on 21.08.2024 [2024/34] | 19.07.2024 | Change - extension states | published on 21.08.2024 [2024/34] | Applicant(s) | For all designated states AnaptysBio, Inc. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 / US | [2024/12] | Inventor(s) | 01 /
PRASEUTH, Alex San Diego, California 92121 / US | 02 /
ZEN, Kevin San Diego, California 92121 / US | 03 /
ALTOBELL III, Laurence San Diego, California 92121 / US | 04 /
MARINO, Margaret H. San Diego, California 92121 / US | [2024/12] | Representative(s) | Hoeger, Stellrecht & Partner Patentanwälte mbB Uhlandstrasse 14c 70182 Stuttgart / DE | [2024/12] | Application number, filing date | 22732712.9 | 12.05.2022 | [2024/12] | WO2022US29043 | Priority number, date | US202163187476P | 12.05.2021 Original published format: US 202163187476 P | [2024/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022241148 | Date: | 17.11.2022 | Language: | EN | [2022/46] | Type: | A1 Application with search report | No.: | EP4337257 | Date: | 20.03.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.11.2022 takes the place of the publication of the European patent application. | [2024/12] | Search report(s) | International search report - published on: | EP | 17.11.2022 | Classification | IPC: | A61K47/02, A61K47/18, A61K47/26, A61K39/395, A61P3/00, A61P11/00, A61P29/00, A61P35/00, A61P37/00 | [2024/12] | CPC: |
A61K9/0019 (EP);
A61K39/39591 (KR,US);
A61K39/395 (EP);
A61K47/02 (EP);
A61K47/183 (EP,KR);
A61K47/22 (KR,US);
A61K47/26 (EP,KR,US);
A61K9/08 (KR,US);
A61P11/00 (EP,KR);
A61P29/00 (EP,KR);
A61P3/00 (EP,KR);
A61P35/00 (EP,KR);
A61P37/00 (EP,KR);
C07K16/244 (KR,US);
C07K16/2866 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/12] | Title | German: | ANTIKÖRPERZUSAMMENSETZUNG | [2024/12] | English: | ANTIBODY COMPOSITION | [2024/12] | French: | COMPOSITION D'ANTICORPS | [2024/12] | Entry into regional phase | 10.11.2023 | National basic fee paid | 10.11.2023 | Designation fee(s) paid | 10.11.2023 | Examination fee paid | Examination procedure | 10.11.2023 | Examination requested [2024/12] | 10.11.2023 | Date on which the examining division has become responsible | 19.06.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 13.03.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2009100297 (MERCK & CO INC [US], et al); | [A]WO2011088120 (AMGEN INC [US], et al); | [X]US2012230982 (ZHOU XIAO-HONG [US], et al); | [X]US2013216556 (FOWLER ADAM JEREMY [US], et al); | [X]WO2015169742 (TAKEDA GMBH [DE]); | [A]WO2016168542 (ANAPTYSBIO INC [US]); | [XI]WO2017194646 (UCB BIOPHARMA SPRL [BE]); | [X]WO2019154397 (BIO THERA SOLUTIONS LTD [CN]); | [I]US2020207862 (BAUM PATRICK [DE], et al); | [X]US2020216524 (CADY ROGER K [US], et al); | [I]US2020282053 (DENKINGER SANDRA NICOLE [DE], et al); | [I]US2021087285 (THOMA CHRISTIAN [DE], et al); | [XP]WO2022000046 (CSL INNOVATION PTY LTD [AU]); | [E]WO2022126173 (CSL INNOVATION PTY LTD [AU]); | [E]WO2022132636 (AMMAX BIO INC [US]) | by applicant | US4828981 | US8568992 |